- Home
- AVT vs ACAD Comparison
AVT vs ACAD Comparison
Compare AVT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVT
- ACAD
- Stock Information
- Founded
- AVT 1921
- ACAD 1993
- Country
- AVT United States
- ACAD United States
- Employees
- AVT N/A
- ACAD N/A
- Industry
- AVT Electronic Components
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- AVT Technology
- ACAD Health Care
- Exchange
- AVT Nasdaq
- ACAD Nasdaq
- Market Cap
- AVT 4.3B
- ACAD 4.3B
- IPO Year
- AVT N/A
- ACAD 2004
- Fundamental
- Price
- AVT $51.74
- ACAD $21.31
- Analyst Decision
- AVT Sell
- ACAD Buy
- Analyst Count
- AVT 3
- ACAD 21
- Target Price
- AVT $49.00
- ACAD $29.25
- AVG Volume (30 Days)
- AVT 714.1K
- ACAD 2.3M
- Earning Date
- AVT 10-29-2025
- ACAD 11-05-2025
- Dividend Yield
- AVT 2.55%
- ACAD N/A
- EPS Growth
- AVT N/A
- ACAD 615.00
- EPS
- AVT 2.75
- ACAD 1.33
- Revenue
- AVT $22,200,754,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- AVT $5.60
- ACAD $14.01
- Revenue Next Year
- AVT $5.99
- ACAD $11.81
- P/E Ratio
- AVT $18.82
- ACAD $16.07
- Revenue Growth
- AVT N/A
- ACAD 14.41
- 52 Week Low
- AVT $39.22
- ACAD $13.40
- 52 Week High
- AVT $59.24
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- AVT 42.97
- ACAD 33.94
- Support Level
- AVT $51.26
- ACAD $21.32
- Resistance Level
- AVT $52.99
- ACAD $21.96
- Average True Range (ATR)
- AVT 0.89
- ACAD 0.60
- MACD
- AVT -0.10
- ACAD -0.10
- Stochastic Oscillator
- AVT 7.18
- ACAD 30.11
About AVT Avnet Inc.
Avnet Inc is an electronic component technology distributor and solutions provider. It serves customers from startups and mid-sized businesses to enterprise-level original equipment manufacturers (OEMs), electronic manufacturing services (EMS) providers, and original design manufacturers (ODMs). The group operates in the Electronic Components segment and supports high and medium-volume customers to markets, sells, and distributes electronic components, and the Farnell segment supports lower-volume customers that need electronic components quickly to develop, prototype, and test their products. Its geographic regions are the Americas, EMEA, and Asia.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.